Vlado Perkovic
Overview
Explore the profile of Vlado Perkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
406
Citations
20782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beal B, Buizen L, Yeung E, Heath L, Houston L, Cherney D, et al.
Nephrol Dial Transplant
. 2025 Mar;
PMID: 40036884
Background: Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on insulin...
2.
Kotwal S, Perkovic V
Kidney Int Rep
. 2025 Feb;
10(2):287-290.
PMID: 39990872
No abstract available.
3.
Chatur S, Vaduganathan M, Fletcher R, Perkovic V, Heerspink H, Arnott C, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39844714
Aims: The sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes...
4.
Siriwardana A, Buizen L, Jun M, Kotwal S, Arnott C, Jardine M, et al.
Diabetes Obes Metab
. 2025 Jan;
27(4):1972-1979.
PMID: 39781601
Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial...
5.
Kotwal S, Perkovic V, Jardine M, Kim D, Shah N, Lin E, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449998.
PMID: 39661388
Importance: Chronic kidney disease (CKD) is a global health priority affecting almost 1 billion people. New therapeutic options and clinical trial innovations such as adaptive platform trials provide an opportunity...
6.
Badve S, Bilal A, Lee M, Sattar N, Gerstein H, Ruff C, et al.
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):15-28.
PMID: 39608381
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains...
7.
Perkovic V, Tuttle K, Pratley R
N Engl J Med
. 2024 Nov;
391(18):1757.
PMID: 39504529
No abstract available.
8.
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al.
N Engl J Med
. 2024 Oct;
392(6):531-543.
PMID: 39453772
Background: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. Methods: In this phase...
9.
Li J, Lv J, Wong M, Shi S, Zan J, Monaghan H, et al.
Kidney Int Rep
. 2024 Oct;
9(10):3016-3026.
PMID: 39430181
Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers...
10.